• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Malabsorption Syndrome Market

    ID: MRFR/Pharma/4014-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Malabsorption Syndrome Market Trends And Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Malabsorption Syndrome Market Infographic
    Purchase Options

    Malabsorption Syndrome Market Summary

    The Global Malabsorption Syndrome Market is projected to grow significantly from 0.21 USD Billion in 2024 to 4.61 USD Billion by 2035.

    Key Market Trends & Highlights

    Malabsorption Syndrome Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 32.42% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 4.61 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 0.21 USD Billion, highlighting its nascent stage.
    • Growing adoption of advanced diagnostic techniques due to increasing awareness of malabsorption syndrome is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.21 (USD Billion)
    2035 Market Size 4.61 (USD Billion)
    CAGR (2025-2035) 32.42%

    Major Players

    Abbvie Inc., AstraZeneca PLC, DSM, Gilead Sciences, Glenmark Pharmaceuticals, Lupin Pharmaceuticals Inc., McNeil Nutritionals, Perrigo, Roche, Vetbiochem India Private Limited, Actelion Pharmaceuticals Ltd, Bayer Healthcare AG, Eli Lily and Company, GlaxoSmithKline plc., KLAIRE LABORATORIES, Mallinckrodt Pharmaceuticals, National Enzyme Company, Pfizer Inc., Sanofi

    Malabsorption Syndrome Market Drivers

    Market Growth Projections

    Increased Awareness and Education

    The Global Malabsorption Syndrome Market Industry benefits from heightened awareness and education regarding malabsorption disorders. Campaigns by health organizations and patient advocacy groups are instrumental in informing the public about symptoms and treatment options. This increased awareness leads to more individuals seeking medical advice, resulting in higher diagnosis rates. As the market evolves, the focus on patient education is likely to enhance treatment adherence and improve health outcomes. The projected growth from 0.21 USD Billion in 2024 to 4.61 USD Billion by 2035 underscores the potential impact of awareness initiatives on market expansion.

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic tools are significantly impacting the Global Malabsorption Syndrome Market Industry. Innovations such as non-invasive tests, genetic screening, and advanced imaging techniques enhance the accuracy of diagnosing malabsorption syndromes. These improvements facilitate earlier detection and treatment, which is crucial for patient outcomes. As healthcare providers adopt these technologies, the market is expected to grow substantially. The anticipated CAGR of 32.42% from 2025 to 2035 indicates a robust expansion driven by enhanced diagnostic capabilities, ultimately leading to better management of malabsorption disorders.

    Growing Demand for Nutritional Supplements

    There is a growing demand for nutritional supplements tailored for individuals with malabsorption syndromes within the Global Malabsorption Syndrome Market Industry. Patients often require specialized diets and supplements to compensate for nutrient deficiencies caused by their conditions. As awareness of these dietary needs increases, manufacturers are developing innovative products to meet this demand. The market's expansion is reflected in the projected growth from 0.21 USD Billion in 2024 to 4.61 USD Billion by 2035. This trend indicates a shift towards personalized nutrition solutions, which are likely to play a crucial role in managing malabsorption disorders.

    Regulatory Support for Treatment Innovations

    Regulatory bodies are increasingly supportive of innovations in treatments for malabsorption syndromes, positively influencing the Global Malabsorption Syndrome Market Industry. Initiatives aimed at expediting the approval process for new therapies and nutritional products are emerging. This regulatory environment encourages research and development, fostering the introduction of novel treatment options. As the market evolves, the anticipated CAGR of 32.42% from 2025 to 2035 suggests that regulatory support will be a key driver of growth, enabling companies to bring effective solutions to patients more rapidly.

    Rising Prevalence of Malabsorption Disorders

    The Global Malabsorption Syndrome Market Industry is witnessing a notable increase in the prevalence of malabsorption disorders. Factors such as dietary changes, increased awareness, and improved diagnostic techniques contribute to this trend. For instance, conditions like celiac disease and lactose intolerance are becoming more recognized, leading to higher diagnosis rates. As of 2024, the market is valued at 0.21 USD Billion, reflecting the growing need for effective treatment options. This rise in prevalence is likely to drive demand for specialized therapies and nutritional products, thereby expanding the market further.

    Key Companies in the Malabsorption Syndrome Market market include

    Industry Developments

      • Many of the key players of the market are adopting various initiatives such as product launches, advancements in equipment technology, and others. Moreover, they are investing a lot in the research and development of the market.

    Future Outlook

    Malabsorption Syndrome Market Future Outlook

    The Global Malabsorption Syndrome Market is projected to grow at a 32.42% CAGR from 2024 to 2035, driven by increasing prevalence, advancements in diagnostics, and rising awareness of gastrointestinal health.

    New opportunities lie in:

    • Develop innovative diagnostic tools leveraging AI for early detection.
    • Expand telehealth services to enhance patient access to specialists.
    • Invest in personalized nutrition solutions tailored for malabsorption patients.

    By 2035, the market is expected to exhibit robust growth, reflecting heightened awareness and improved treatment options.

    Market Segmentation

    By end-user

    • Others
    • Nutrition Clinics
    • Pharmaceutical companies
    • Academic and Research Institutes
    • Hospitals

    By diagnosis

    • C-d-xylose breath test
    • Test of bile salt absorption
    • D-xylose test
    • Schilling test
    • Tests of carbohydrate absorption
    • Test of fat malabsorption
    • Other tests
    • Hematologic tests
    • Abdominal x-ray
    • Magnetic resonance cholangiopancreatography (MRCP)
    • Endoscopic retrograde cholangiopancreatogram (ERCP)
    • Ct scan
    • Imaging studies
    • Others
    • Antidiarrheal agents
    • Protease and lipase supplements
    • Nutritional supplements
    • Antibiotics
    • Anti-inflammatory drugs
    • Gluten-free diet
    • Others
    • Nutrition Clinics
    • Pharmaceutical companies
    • Academic and Research Institutes
    • Hospitals

    By treatment 

    • Others
    • Antidiarrheal agents
    • Protease and lipase supplements
    • Nutritional supplements
    • Antibiotics
    • Anti-inflammatory drugs
    • Gluten-free diet
    • Others
    • Nutrition Clinics
    • Pharmaceutical companies
    • Academic and Research Institutes
    • Hospitals

    Geographically

    • Rest of the world
    • Middle East & Africa
    • North America
    • Asia-Pacific
    • Europe

    Report Overview 

    • Rest of the world
    • Middle East & Africa
    • North America
    • Asia-Pacific
    • Europe

    By causative diseases

    • Others
    • Tropical sprue
    • Whipple’s disease
    • Lactose intolerance
    • Others
    • Celiac disease
    • Intestinal disorders
    • Parasitic diseases
    • Cystic fibrosis
    • C-d-xylose breath test
    • Test of bile salt absorption
    • D-xylose test
    • Schilling test
    • Tests of carbohydrate absorption
    • Test of fat malabsorption
    • Other tests
    • Hematologic tests
    • Abdominal x-ray
    • Magnetic resonance cholangiopancreatography (MRCP)
    • Endoscopic retrograde cholangiopancreatogram (ERCP)
    • Ct scan
    • Imaging studies
    • Others
    • Antidiarrheal agents
    • Protease and lipase supplements
    • Nutritional supplements
    • Antibiotics
    • Anti-inflammatory drugs
    • Gluten-free diet
    • Others
    • Nutrition Clinics
    • Pharmaceutical companies
    • Academic and Research Institutes
    • Hospitals

    Recent Developments 

    • Many of the key players of the market are adopting various initiatives such as product launches, advancements in equipment technology, and others. Moreover, they are investing a lot in the research and development of the market.

    Malabsorption Syndrome Market Key Players

    • Sanofi
    • Pfizer Inc.
    • National Enzyme Company
    • Mallinckrodt Pharmaceuticals
    • KLAIRE LABORATORIES
    • GlaxoSmithKline plc.
    • Eli Lily and Company
    • Bayer Healthcare AG
    • Actelion Pharmaceuticals Ltd
    • Vetbiochem India Private Limited
    • Roche
    • Perrigo
    • McNeil Nutritionals
    • Lupin Pharmaceuticals Inc.
    • Glenmark Pharmaceuticals
    • Gilead Sciences
    • DSM
    • AstraZeneca PLC
    • Abbvie Inc.

    Malabsorption Syndrome Market Segmentation

    • Others
    • Tropical sprue
    • Whipple’s disease
    • Lactose intolerance
    • Others
    • Celiac disease
    • Intestinal disorders
    • Parasitic diseases
    • Cystic fibrosis
    • C-d-xylose breath test
    • Test of bile salt absorption
    • D-xylose test
    • Schilling test
    • Tests of carbohydrate absorption
    • Test of fat malabsorption
    • Other tests
    • Hematologic tests
    • Abdominal x-ray
    • Magnetic resonance cholangiopancreatography (MRCP)
    • Endoscopic retrograde cholangiopancreatogram (ERCP)
    • Ct scan
    • Imaging studies
    • Others
    • Antidiarrheal agents
    • Protease and lipase supplements
    • Nutritional supplements
    • Antibiotics
    • Anti-inflammatory drugs
    • Gluten-free diet
    • Others
    • Nutrition Clinics
    • Pharmaceutical companies
    • Academic and Research Institutes
    • Hospitals

    Report Scope

    Report Attribute/Metric Details
      Market Size 2032   USD 3.82 Billion
      CAGR   6.48% (2024-2032)
      Base Year   2023
      Forecast Period   2024-2032
      Historical Data   2022
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Diagnosis, Causative Diseases, Treatment and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors    Abbvie, Inc., Actelion Pharmaceuticals Ltd, AstraZeneca PLC, Bayer Healthcare AG, DSM, Eli Lily and Company, Gilead Sciences, GlaxoSmithKline plc, Glenmark Pharmaceuticals, KLAIRE LABORATORIES, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, McNeil Nutritionals, National Enzyme Company, Perrigo, Pfizer, Inc., Roche, Sanofi, Vetbiochem India Private Limited
      Key Market Opportunities   Rising healthcare expenditure in the developed countries and improving regulatory framework
      Key Market Drivers   Rising cases of causative diseases such as celiac disease, and others

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    At what CAGR is the malabsorption syndrome market projected to grow during the forecast period?

    malabsorption syndrome market is projected to grow at an 6.48% CAGR between 2024-2032.

    Which region is expected to dominate the malabsorption syndrome market?

    The Americas is expected to dominate the malabsorption syndrome market.

    What are the key factors adding to the malabsorption syndrome market growth?

    Rising healthcare expenditure and favorite reimbursement policies are the key factors adding to the malabsorption syndrome market growth.

    Which factors may limit the malabsorption syndrome market growth?

    Poor healthcare system and certain side effects may limit the malabsorption syndrome market growth.

    Name the major end users of the malabsorption syndrome market.

    Major end users of the malabsorption syndrome market include academic and research institutes, nutrition clinics, hospitals, pharmaceutical companies, and others.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials